ImmunoGen, Inc.

The Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030 report highlights the transformative potential of ADCs in cancer treatment, with 16 approved products and sales exceeding US$ 10 Billion in 2023. The market is projected to reach over US$ 50 Billion by 2030, driven by ongoing clinical trials and increasing R&D efforts. Key players include Enhertu, Kadcyla, and Padcev, with significant development activity focused on lung and breast cancers.

The immunoglobulin market, valued at US$ 13.36 billion in 2023, is projected to reach US$ 28.70 billion by 2034, driven by its use in treating immunodeficiency and other applications. Key growth factors include immunodeficiency disorders, infections, and thrombocytopenia. North America leads with a 46% share, while Asia-Pacific is expected to grow fastest due to increased health spending and prevalence of autoimmune diseases. Recent advancements include subcutaneous injection therapies and acquisitions by major pharmaceutical companies.

The global immunomodulators market is projected to grow from $317.06 billion in 2024 to $1,237.66 billion by 2034, driven by their use in treating autoimmune diseases, cancer, preventing infections, and managing organ transplant rejection. Key factors include advancements in precision medicine, regional growth in Asia-Pacific, and recent acquisitions and partnerships in the sector.

S.B., A.D., T.J.F., I.M.G., L.G., R.K.J., G.K., J.M.L., G.V.L., K.P.-J., H.I.S., J.T., R.R.W., M.W., Y.L.W. have disclosed various financial interests, including funding, advisory roles, patents, and equity. C.M.B., E.B., M.W.B., and K.P. declare no competing interests.

EMA’s CHMP recommended AbbVie’s ovarian cancer drug Elahere for approval in the EU, based on the MIRASOL study showing a 35% reduction in tumor progression or death. The EC will review this recommendation, with a decision expected later this year.

DelveInsight's 'Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight 2024' covers 50+ companies and 75+ pipeline drugs, including clinical and nonclinical stage products, with therapeutic assessments by product type, stage, route of administration, and molecule type. Key companies and therapies highlighted.

CEACAM5 drugs market to grow significantly due to rising cancer diagnoses and clinical trials; no CEACAM5 drugs currently approved. Key companies developing CEACAM5 drugs include Merck KGaA, Sanofi, and Roche. Emerging therapies like SGM-101 and M9140 show promise in clinical trials.

Kura Oncology appoints Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles brings over 25 years of oncology drug development experience and leadership. He is currently a Senior Advisor at Frazier Healthcare Partners and has held senior roles at ImmunoGen, Flatiron Health, Unum Therapeutics, Takeda/Millennium, and Genzyme Corporation. Dr. Vasconcelles expressed enthusiasm for Kura's precision oncology approach and its menin inhibitor program for acute leukemias.

TORL-1-23, a CLDN6-targeted ADC, showed responses in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer, with a well-tolerated safety profile. The ORR was 26% at doses <2.4 mg/kg, 42% at 2.4 mg/kg, and 31% at 3.0 mg/kg, with a complete response rate of 4% at the highest dose. Neutropenia risk was mitigated by prophylactic pegfilgrastim, and the MTD was not yet reached.